Jing Liu, Yanwen Song, Qin Liu, Li Li, Junping Pan, Lan Luo, Shitao Zhu, Dongmei Wu, Dan Hu, Qin Xu
{"title":"Prognostic significance of chemotherapy response score in predicting outcomes for high-grade serous ovarian carcinoma patients undergoing neoadjuvant chemotherapy.","authors":"Jing Liu, Yanwen Song, Qin Liu, Li Li, Junping Pan, Lan Luo, Shitao Zhu, Dongmei Wu, Dan Hu, Qin Xu","doi":"10.21037/tcr-24-1654","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The chemotherapy response score (CRS) evaluates the response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC). This study aimed to develop a prognostic nomogram combining CRS and clinical characteristics to improve outcome predictions for NACT-treated patients.</p><p><strong>Methods: </strong>We retrospectively analyzed 271 HGSOC patients who received NACT. Univariate and multivariate regression analyses were conducted to identify independent prognostic factors, which were then used to construct a nomogram. The nomogram's performance was evaluated using the concordance index (C-index), calibration plots, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>Patients were randomly divided into the training cohort (n=181) and validation cohort (n=90). Cox regression analysis identified debulking status, CRS, and post-adjuvant chemotherapy cancer antigen 125 (PACT-CA125) levels as independent prognostic factors, which were incorporated into the nomogram. The nomogram demonstrated C-indices of 0.735 and 0.730 in the training and validation cohorts, respectively. The ROC curves, calibration plots, and DCA confirmed the nomogram's strong predictive performance. Notably, longer progression-free survival was observed in patients with <3 cycles of adjuvant chemotherapy in low-risk groups, while similar findings were not obtained in the high-risk group.</p><p><strong>Conclusions: </strong>This study developed a novel prognostic nomogram incorporating debulking status, CRS and PACT-CA125 levels for NACT-treated HGSOC patients. It serves as a valuable tool for personalized treatment planning and survival assessment, assisting clinicians in making individualized decisions.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 4","pages":"2319-2330"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079240/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1654","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The chemotherapy response score (CRS) evaluates the response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC). This study aimed to develop a prognostic nomogram combining CRS and clinical characteristics to improve outcome predictions for NACT-treated patients.
Methods: We retrospectively analyzed 271 HGSOC patients who received NACT. Univariate and multivariate regression analyses were conducted to identify independent prognostic factors, which were then used to construct a nomogram. The nomogram's performance was evaluated using the concordance index (C-index), calibration plots, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).
Results: Patients were randomly divided into the training cohort (n=181) and validation cohort (n=90). Cox regression analysis identified debulking status, CRS, and post-adjuvant chemotherapy cancer antigen 125 (PACT-CA125) levels as independent prognostic factors, which were incorporated into the nomogram. The nomogram demonstrated C-indices of 0.735 and 0.730 in the training and validation cohorts, respectively. The ROC curves, calibration plots, and DCA confirmed the nomogram's strong predictive performance. Notably, longer progression-free survival was observed in patients with <3 cycles of adjuvant chemotherapy in low-risk groups, while similar findings were not obtained in the high-risk group.
Conclusions: This study developed a novel prognostic nomogram incorporating debulking status, CRS and PACT-CA125 levels for NACT-treated HGSOC patients. It serves as a valuable tool for personalized treatment planning and survival assessment, assisting clinicians in making individualized decisions.
期刊介绍：
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
